Krystal Biotech awarded director Janney Daniel 1,658 derivative securities at $0 per share on 2026-09-14. The terms matter to investors because they identify a zero-price award or grant, rather than a purchase or sale, and specify the security type and recipient tied to the company.

Key Highlights

  • Janney Daniel is identified as a director of Krystal Biotech, Inc.
  • The transactions carry SEC transaction code A.
  • Krystal Biotech, Inc. is listed on Nasdaq under KRYS.

Krystal Biotech, Inc. (NASDAQ: KRYS) awarded Janney Daniel 1,658 derivative securities at $0 per share on 14 September 2026. Daniel is identified as a director of Krystal Biotech, Inc.

1,658 Derivative Securities Awarded

The award was recorded through two transactions carrying SEC transaction code A. The instrument involved was derivative securities, and the disclosed price was $0 per share. Janney Daniel was the named recipient. The transaction date was 14 September 2026. Krystal Biotech, Inc. linked the award to its director, Janney Daniel. The disclosed terms identify the security type, transaction classification and price attached to the award. Transaction code A denotes an award, grant, or other Acquisition from the company.